Skip to main content
. Author manuscript; available in PMC: 2010 Apr 9.
Published in final edited form as: Cytokine. 2008 Apr 8;42(3):277–288. doi: 10.1016/j.cyto.2008.03.002

Figure 3.

Figure 3

A timeline of major events in the development and use of G-CSF in the clinic. Left to right, the timeline highlights principal findings that are relevant to the therapeutic use of G-CSF including the initial description of congenital neutropenia [163] and leukemia in SCN [184], purification and cloning of human G-CSF [12, 15, 16], first clinical use of G-CSF for neutropenia resulting from chemotherapy or congenital origin [36, 37, 152–154], cloning of G-CSFR and identification of receptor functional domains [63, 64, 80–82], initial reports of G-CSFR mutations in SCN [155–157], functional studies of G-CSFR mutants found in SCN [95, 96, 110, 161], and associations between the therapeutic use of G-CSF and the development of MDS/AML [9, 170, 185]. Due to space limitations, all significant references could not be included. (Timeline: Purple, 1956-1959; Pink, 1960-1969; Yellow, 1970-1979; Green, 1980-1989; Blue, 1990-1999; Red, 2000-present)